Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.
Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...
The signs of aortic stenosis on physical ... that has FDA approval is the Edwards SAPIEN valve with the Retroflex3 system. It is a trileaflet valve made from bovine pericardium in a stainless ...
(B) The Edwards Sapien™ (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional aortic valve.
Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...
Why it matters: Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue from new transcatheter mitral and tricuspid ...
Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results